Article
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.
Leukemia - 1 Jan 2016
Mayado A, Teodosio C, Garcia-Montero A C, Matito A, Rodriguez-Caballero A, Morgado J M, Muñiz C, Jara-Acevedo M, Álvarez-Twose I, Sanchez-Muñoz L, Matarraz S, Caldas C, Muñoz-González J I, Escribano L, Orfao A
Abstract excerpt
Systemic mastocytosis (SM) is a heterogeneous disease with altered interleukin (IL)-6 and IL13 plasma levels. However, no study has simultaneously investigated the plasma levels of IL1β, IL6, IL13, CCL23 and clusterin in SM at diagnosis and correlated them with disease outcome. Here we investigated IL1β, IL6, IL13, CCL23 and clusterin plasma levels in 75 SM patients--66 indolent SM (ISM) and 9 aggressive SM--and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.